K-ras mutations in colorectal cancer at different stages

Tumor

Volumn 30, Issue 2, 2010, Pages 134-137

  Shen, Yong Qi ^a   Ye, Yun Bin ^a   Zheng, Xiong Wei ^a   Li, Chao ^a   Chen, Qiang ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal neoplasms; DNA mutational analysis; Genes, ras; Mutation

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; ONCOGENE K RAS; POLYMERASE CHAIN REACTION;

EID: 77953445806     PISSN: 10007431     EISSN: None     Source Type: Journal    
DOI: 10.3781/j.issn.1000-7431.2010.02.010     Document Type: Article

References (15)

1. FEARON E R, VOGELSTEIN B A. A genetic model for colorectal tumorigenesis [J]. Cell, 1990, 61(5):759-767.
2. Chinese source
3. Chinese source
4. MINAMOTO T, MAI M, RONAI Z. K-ras mutation early detection in molecular diagnosis and risk and assessment of colorectal pancreas and lung cancers [J]. Cancer Detect Prev, 2000, 24(1):1-12.
5. BRINK M, DE GOEIJ A F, WEIJENBERG M P, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands COIIORT Study [J]. Carcinogenesis, 2003, 24(4):703-710.
6. VAN CUTSEM E, NOWACKI M, LANG I, et al. Randomized phase III study of irinotecan and 5-Fu/FA with or without cetuximab in the first-line treatment of patiants with metastatic colorectal cancer (mCRC) : the CRYSTAL trial [J]. Proc Am Soc Clin oncol, 2007, 25(Suppl):185-185.
7. TANG W Y, ELNATAN I, LEE Y S, et al. c-K-ras mutation in colorectal adenocarcinomas from a country with a rapidly changing colorectal cancer incidence. [J]. Br J Cancer, 1999, 81(2):237-241.
8. Chinese source
9. Chinese source
10. DIETERLE C P, CONZELMIANN M, LINNEMANN U, et al. Detections of isolated tumor cells by polymerase chain reactions restriction fragment length polymorphism for K-ras mutations in tissue samples of 199 colorectal cancer patients [J]. Clin Cancer Res, 2004, 10(2):641-650.
11. SCIILMANSKI C C, LINNEMANN U, BERGER M R, et al. Sensitive detection of K-ras mutation augments diagnosis of colorectal cancer metastases in the liver [J]. Cancer Res, 1999, 59(20):5169-5175.
12. LIEVRE A, BACIIET J B, Le CORRE D, et al. K-ras mutation status is predictive of response to Cetuximab therapy in colorectal cancer [J]. Cancer Res, 2006, 66(8):3992-3995.
13. KIIAMBATA-FORD S, GARRETT C R, MEROPOL N J, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab [J]. J Clin Oncol, 2007, 25(22):3230-3237.
14. TEJPAR S, PEETERS M, IIUMBLET Y, et al. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatie colorectal cancer ( mCRC ), treated with irinotecan (q2w) and escalating doses of cetuximiab (qlw): the EVEREST experince (preliminary date) [J]. J Clin Oncol, 2008, 26(Suppl):4001.
15. VAN CUTSEM E, LANG I, DIIAENS G, et al. K-RAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIR1 with or without cetuximab: the CRYTAL experience [J]. J Clin Oncol, 2008, 26 (Suppl):2.